Bleeding Gastric Varices Obliteration with Balloon-occluded Retrograde Transvenous Obliteration Using Sodium Tetradecyl Sulfate Foam

被引:82
|
作者
Sabri, Saher S. [1 ]
Swee, Warren [1 ]
Turba, Ulku C. [1 ]
Saad, Wael E. A. [1 ]
Park, Auh W. [1 ]
Al-Osaimi, Abdullah M. [2 ]
Caldwell, Stephen H. [2 ]
Matsumoto, Alan H. [1 ]
Angle, John F. [1 ]
机构
[1] Univ Virginia Hlth Syst, Div Angiog Intervent Radiol & Special Procedures, Dept Radiol, Charlottesville, VA 22908 USA
[2] Univ Virginia Hlth Syst, Div Gastroenterol, Dept Med, Charlottesville, VA 22908 USA
关键词
INTRAHEPATIC PORTOSYSTEMIC SHUNT; TERM-FOLLOW-UP; TRANSCATHETER OBLITERATION; FUNDAL VARICES; SCLEROTHERAPY; MANAGEMENT; HEMORRHAGE; INJECTION; CYANOACRYLATE; VARICOCELE;
D O I
10.1016/j.jvir.2010.11.022
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: Balloon-occluded retrograde transvenous obliteration (BRTO) of bleeding gastric varices (GV) is well described in the literature. Using Ethanolamine oleate as the sclerosing agent in BRTO, but it is not readily available in the United States in the desired concentrations. The authors' aim is to describe their initial experience with BRTO using sodium tetradecyl sulfate (STS) foam as an alternative sclerosing agent. Materials and Methods: The authors performed a retrospective review of heir initial series in which STS foam was used to treat bleeding GV using BRTO. All study subjects had endoscopic evidence of gastric variceal bleeding. STS foam was made using a combination of agents with a 3:2:1 ratio of gas: 3% STS: Lipiodol (Ethiodol; Savage Laboratories, Melville, New York). Mean values and ranges were calculated for each variable, and clinical and imaging outcomes were assessed. Results: The authors performed BRTO in 22 cirrhotic patients (11 men and 11 women) with a mean age of 52 years (range, 23-83 years). Technical success was achieved in 20 of 22 (91%) patients. Complications occurred in three of 22 (14%) patients. The overall mean dose of STS used was 300 mg (range, 30-600 mg) with mean total volume of sclerosant mixture of 34.1 mL (range, 10-65 mL). Follow-up imaging was available for 18 of 20 (90%) technically successful procedures with a mean period of 89 days (range, 1-359 days). Complete obliteration of GV was achieved in 16 of 18(89%) patients. There were no cases of recurrent variceal bleeding with a mean clinical follow-up period of 130 days (range, 1-510). Conclusions: BRTO utilizing STS foam appears effective in obliterating bleeding GVs with good short-term outcomes.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 50 条
  • [41] Portal hemodynamics and clinical outcomes of patients with gastric varices after balloon-occluded retrograde transvenous obliteration
    Kasuga, Akiyoshi
    Mizumoto, Hideaki
    Matsutani, Shoichi
    Kobayashi, Akitoshi
    Endo, Tsunehiro
    Ando, Takeshi
    Yukisawa, Seigo
    Maruyama, Hitoshi
    Yokosuka, Osamu
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2010, 17 (06) : 898 - 903
  • [42] Management of Gastric Varices in the Pediatric Population with Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) Utilizing Sodium Tetradecyl Sulfate Foam Sclerosis with or without Partial Splenic Artery Embolization
    Saad, Wael E. A.
    Anderson, Curtis L.
    Patel, Rahul S.
    Schwaner, Sandra
    Caldwell, Stephen
    Pelletier, Shawn
    Angle, John
    Matsumoto, Alan H.
    Fischman, Aaron M.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2015, 38 (01) : 236 - 241
  • [43] Safety and Efficacy of Sodium Tetradecyl Sulfate and Lipiodol Foam in Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for Large Porto-Systemic Shunts
    Mukund, Amar
    Deogaonkar, Ganesh
    Rajesh, S.
    Shasthry, Saggerre Muralikrishna
    Sarin, Shiv Kumar
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (07) : 1010 - 1016
  • [44] Recent development of balloon-occluded retrograde transvenous obliteration
    Kobayakawa, Masao
    Ohnishi, Shin
    Suzuki, Hidekazu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (03) : 495 - 500
  • [45] Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding
    Gimm, Geunwu
    Chang, Young
    Kim, Hyo-Cheol
    Shin, Aesun
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Hwan
    Kim, Yoon Jun
    GUT AND LIVER, 2018, 12 (06) : 704 - 713
  • [46] Predictive Factors of Worsening of Esophageal Varices After Balloon-Occluded Retrograde Transvenous Obliteration in Patients With Gastric Varices
    Elsamman, Mahmoud K.
    Fujiwara, Yasuhiro
    Kameda, Natsuhiko
    Okazaki, Hirotoshi
    Tanigawa, Tetsuya
    Shiba, Masatsugu
    Tominaga, Kazunari
    Watanabe, Toshio
    Oshitani, Nobuhide
    Arafa, Usama A.
    El-Sayed, Adel A.
    Nakamura, Kenji
    Arakawa, Tetsuo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (09) : 2214 - 2221
  • [47] Impact of balloon-occluded retrograde transvenous obliteration on management of isolated fundal gastric variceal bleeding
    Akahoshi, Tomohiko
    Tomikawa, Morimasa
    Kamori, Masao
    Tsutsumi, Norifumi
    Nagao, Yoshihiro
    Hashizume, Makoto
    Maehara, Yoshihiko
    HEPATOLOGY RESEARCH, 2012, 42 (04) : 385 - 393
  • [48] The efficacy of balloon-occluded retrograde transvenous obliteration on small intestinal variceal bleeding
    Hashimoto, Naotaka
    Akahoshi, Tomohiko
    Yoshida, Daisuke
    Kinjo, Nao
    Konishi, Kozo
    Uehara, Hideo
    Nagao, Yoshihiro
    Kawanaka, Hirofumi
    Tomikawa, Morimasa
    Machara, Yoshihiko
    SURGERY, 2010, 148 (01) : 145 - 150
  • [49] Balloon-occluded retrograde transvenous obliteration for recurrent fundal gastric variceal bleeding in an adolescent
    Rosen, Danya
    Chu, Jaime
    Patel, Rahul
    Moon, Jang
    Iyer, Kishore
    Arnon, Ronen
    PEDIATRIC TRANSPLANTATION, 2014, 18 (06) : E193 - E196
  • [50] Letter to the Editor: Is Balloon-Occluded Retrograde Transvenous Obliteration Superior to Endoscopic Cyanoacrylate in Gastric Varices?
    Chinnadurai, Krishna Kumar
    De, Arka
    Duseja, Ajay
    Singh, Virendra
    HEPATOLOGY, 2021, 74 (05) : 2907 - 2908